CO2020015167A2 - Variante de antígeno de virus de varicela zóster y uso de la misma - Google Patents

Variante de antígeno de virus de varicela zóster y uso de la misma

Info

Publication number
CO2020015167A2
CO2020015167A2 CONC2020/0015167A CO2020015167A CO2020015167A2 CO 2020015167 A2 CO2020015167 A2 CO 2020015167A2 CO 2020015167 A CO2020015167 A CO 2020015167A CO 2020015167 A2 CO2020015167 A2 CO 2020015167A2
Authority
CO
Colombia
Prior art keywords
antigen variant
varicella zoster
zoster virus
vaccine
virus antigen
Prior art date
Application number
CONC2020/0015167A
Other languages
English (en)
Inventor
Hyo Jung Nam
Ga Young Ji
Eunmi Kim
Original Assignee
Mogam Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Inst Biomedical Res filed Critical Mogam Inst Biomedical Res
Publication of CO2020015167A2 publication Critical patent/CO2020015167A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16771—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una variante de antígeno y un uso de la misma, siendo la variante de antígeno una proteína, entre las proteínas de superficie (gE) del virus varicela zóster, que presenta un alto nivel de expresión y alta inmunogenicidad, y por lo tanto, cuando se usa la variante de antígeno como composición de vacuna, la composición de vacuna tiene una seguridad más excelente en comparación con una vacuna de virus vivo, y la variante de antígeno presenta un nivel de expresión más alto en una célula hospedera en comparación con otros antígenos y, por lo tanto, es útil como vacuna para prevenir o tratar la varicela o el herpes zóster causado por el virus varicela zóster.
CONC2020/0015167A 2018-05-23 2020-12-02 Variante de antígeno de virus de varicela zóster y uso de la misma CO2020015167A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180058219 2018-05-23
PCT/KR2019/006113 WO2019225962A1 (ko) 2018-05-23 2019-05-22 바리셀라 조스터 바이러스의 항원 변이체 및 이의 용도

Publications (1)

Publication Number Publication Date
CO2020015167A2 true CO2020015167A2 (es) 2020-12-21

Family

ID=68616069

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0015167A CO2020015167A2 (es) 2018-05-23 2020-12-02 Variante de antígeno de virus de varicela zóster y uso de la misma

Country Status (19)

Country Link
US (1) US11642408B2 (es)
EP (1) EP3812394A4 (es)
JP (1) JP7247226B2 (es)
KR (1) KR20210006460A (es)
CN (1) CN112189017A (es)
AU (1) AU2019272184B2 (es)
BR (1) BR112020023642A2 (es)
CA (1) CA3100462A1 (es)
CO (1) CO2020015167A2 (es)
EA (1) EA202092828A1 (es)
IL (1) IL278892A (es)
MA (1) MA51945B2 (es)
MX (1) MX2020012469A (es)
MY (1) MY195490A (es)
PE (1) PE20201415A1 (es)
PH (1) PH12020552009A1 (es)
UA (1) UA126460C2 (es)
WO (1) WO2019225962A1 (es)
ZA (1) ZA202006956B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102270048B1 (ko) 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN113683704B (zh) * 2021-07-28 2023-05-30 安徽智飞龙科马生物制药有限公司 一种水痘-带状疱疹病毒r-gE融合蛋白、重组水痘-带状疱疹疫苗及其制备方法和应用
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023122774A1 (en) 2021-12-23 2023-06-29 Dynavax Technologies Corporation Immunogenicity of a cpg-adjuvanted herpes zoster vaccine
CN116655748A (zh) * 2023-02-28 2023-08-29 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
CN117683121B (zh) * 2024-01-30 2024-04-16 北京百普赛斯生物科技股份有限公司 抗水痘-带状疱疹病毒抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
CA2068654C (en) * 1990-10-04 2011-01-04 Abbas Vafai Varicella-zoster virus antigen
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
WO2006128026A2 (en) * 2005-05-26 2006-11-30 The United States Of America As Represented By Thesecretary, Dept. Of Health And Human Services National Institutes Of Health Cellular receptor for varicella-zoster virus, methods of inhibiting spread of varicella-zoster and methods of increasing stability and infectivity of the virus
KR20140007404A (ko) * 2011-01-31 2014-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법
WO2012115474A2 (ko) * 2011-02-24 2012-08-30 재단법인 목암생명공학연구소 신규한 수두 대상포진 바이러스주 및 이를 이용한 수두 및 대상포진 바이러스 백신
CN102517302A (zh) * 2011-12-28 2012-06-27 中国人民解放军军事医学科学院野战输血研究所 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
CN105669838B (zh) * 2014-12-04 2020-10-16 厦门大学 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
US20180008700A1 (en) * 2014-12-18 2018-01-11 Glaxosmithkline Biologicals S.A. Vaccination
EP3262075B1 (en) * 2015-02-25 2024-03-13 Mogam Institute For Biomedical Research Novel antibody binding to tfpi and composition comprising the same
JP6367783B2 (ja) 2015-11-26 2018-08-01 田中貴金属工業株式会社 水痘帯状疱疹ウイルス検出用免疫クロマト分析装置

Also Published As

Publication number Publication date
AU2019272184A1 (en) 2021-01-14
PE20201415A1 (es) 2020-12-07
JP2021525079A (ja) 2021-09-24
CN112189017A (zh) 2021-01-05
JP7247226B2 (ja) 2023-03-28
MX2020012469A (es) 2021-02-09
BR112020023642A2 (pt) 2021-02-17
UA126460C2 (uk) 2022-10-05
EP3812394A4 (en) 2022-03-23
IL278892A (en) 2021-01-31
CA3100462A1 (en) 2019-11-28
AU2019272184B2 (en) 2022-01-27
WO2019225962A1 (ko) 2019-11-28
MY195490A (en) 2023-01-26
US11642408B2 (en) 2023-05-09
MA51945A1 (fr) 2021-09-30
US20210187099A1 (en) 2021-06-24
PH12020552009A1 (en) 2021-06-14
KR20210006460A (ko) 2021-01-18
ZA202006956B (en) 2022-03-30
MA51945B2 (fr) 2023-08-31
EP3812394A1 (en) 2021-04-28
EA202092828A1 (ru) 2021-03-11

Similar Documents

Publication Publication Date Title
CO2020015167A2 (es) Variante de antígeno de virus de varicela zóster y uso de la misma
CL2018001051A1 (es) Vacunas de ácido nucleico contra el virus varicela zoster (vzv)
CO2018005258A2 (es) Vacuna del virus herpes simple
UY36538A (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
CY1121215T1 (el) Αντιικα εμβολια με βελτιωμενη κυτταρικη ανοσογονικοτητα
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
CY1120489T1 (el) Εμβολια για hsv-2
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CO2019000968A2 (es) Anticuerpos anti-virus del zika y métodos de uso
PE20220379A1 (es) Suministro de biomoleculas a pbmc para modificar una respuesta inmune
CL2020000937A1 (es) Anticuerpo multiespecífico.
ES2627330T3 (es) Uso de JAZ5a para mejorar la resistencia a la sequía en una planta
CO2018012513A2 (es) Anticuerpos
AR110632A1 (es) Vectores del adenovirus canino
AR108781A1 (es) Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
BR112014024751A2 (pt) antígenos de clostridium difficile
AR101814A1 (es) Partícula de tipo virus flavivirus
AR110458A1 (es) Vacunas de fmdv vectorizadas con adenovirus recombinantes y usos de las mismas
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna